Open Access

Differential expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules; a potential diagnostic tool?

  • Matthew D Brace1,
  • Jun Wang2,
  • Mark Petten2,
  • Martin J Bullock3,
  • Fawaz Makki1,
  • Jonathan Trites1,
  • S Mark Taylor1 and
  • Robert D Hart1Email author
Journal of Otolaryngology - Head & Neck Surgery201443:22

https://doi.org/10.1186/s40463-014-0022-x

Received: 21 January 2014

Accepted: 27 June 2014

Published: 18 July 2014

Abstract

Background

Thyroid nodules are common, but only 5% of nodules are found to be malignant. In North America, the incidence of thyroid cancer is increasing. Fine needle aspirate (FNA) biopsy is the diagnostic test of choice. Unfortunately, up to 20% of FNAs are non-diagnostic. A specific molecular marker for thyroid cancer is desirable. Evidence suggests that cell signaling through transforming growth factor beta (TGF- β) is important in the development of thyroid cancer. We sought to compare the expression of TGF- β in malignant and benign thyroid nodules.

Methods

From 2008-present, thyroid nodule tissue from thyroidectomy specimens was prospectively collected and stored at −80°C. RNA extraction and reverse transcription was performed on 47 samples (24 papillary thyroid cancer and 23 benign nodules). Quantitative PCR using SYBR green was performed to detect TGF-β-1 and −2. Resulting CT values were normalized against β-actin. Gene expression was calculated using the 2-ΔCT method.

Results

A significantly greater expression of TGF- β1 (p < 0.0001) was detected in the group of malignant thyroid nodules compared to benign nodules. There was no difference in the expression of TGF- β2 (p = 0.4735) between the two groups.

Conclusions

In this study, we demonstrated that expression of TGF- β1 but not TGF- β2 is significantly increased in papillary thyroid cancer compared to benign thyroid nodules. This may serve as a potential diagnostic marker for papillary thyroid cancer.

Keywords

Thyroid cancerPapillaryTransforming growth factor beta

Introduction

Thyroid cancer is an uncommon malignancy; however, its incidence has increased by an average of 6.8% per year for males and 8.8% for females between 1998 and 2007 in Canada [[1]]. Papillary thyroid cancer (PTC) accounts for over 80% of all thyroid cancer cases [[2]]. Despite well-defined histological parameters, thyroid cancer patients do not have specific clinic presentations other than palpable nodules. An accurate clinical diagnosis prior to surgery has proven difficult due to the lack of specific diagnostic tests for thyroid cancer.

Fine needle aspiration (FNA) biopsy is a commonly used diagnostic technique for thyroid nodules; however, up to 20% of initial FNAs are non-diagnostic. Of these 2-51% will be malignant [[3]–[5]]. Current recommendations in the management of patients with non-diagnostic FNAs advocate repeating the FNA, or pursuing hemithyroidectomy for definitive pathological diagnosis [[2],[4]]. Consequently, a large portion of thyroid surgery (40-60%) is performed on what is later diagnosed as benign disease [[4]–[6]]. Development of reliable and accurate pre-operative diagnostic tests to differentiate thyroid cancer from benign thyroid nodules is critical to reduce unnecessary cost to our health care system, and potential patient morbidity.

The transforming growth factor β (TGF-β) cytokine family contains 33 members, of which, three TGF-β isoforms are included, as well as activins, bone morphogenic proteins, and growth differentiation proteins [[7]–[10]]. TGF-β achieves intracellular signaling via phosphorylation of the Smad2 and Smad3 proteins which complex with Smad4 and translocate to the nucleus to regulate gene expression [[7]–[12]]. In PTC cell lines and animal models, TGF-β signaling has been shown to regulate cellular epithelial to mesenchymal transition [[10],[12],[13]]. Embryologically, TGF-β acts as a potent inducer of apoptosis, fundamental to normal development [[9]]. In adult cells, TGF-β retains its effect as a potent inducer of apoptosis, and also acts to promote immune regulation and angiogenesis, acting as a tumor suppressor gene [[8],[9],[11],[12]].

In cancer, animal models demonstrate that the role of TGF-β is complicated. TGF-β initially retains its tumor suppressor properties, but, as cells lose their response to apoptotic signals during tumor development, TGF-β becomes a tumor promoter gene [[8]–[11]]. Through the additive effect of immune suppression, promotion of angiogenesis, and epithelial to mesenchymal transition, TGF-β acts to promote invasive tumors with a propensity for metastasis. In situ hybridization and immunohistochemical studies on human thyroid tissues have previously demonstrated increased TGF-β in thyroid cancer, and in some instances, in multinodular goiter [[7],[10],[14],[15]].

In this pilot study, we endeavored to determine whether or not in vivo expression of TGF-β1 and TGF-β2 in human thyroid nodules differed between patients with PTC and those with benign nodular changes.

Materials and methods

Patient selection and sample collection

Ethics approval for this study was obtained through Capital Health Halifax’s ethics department. Informed consent allowing the collection and storage of resected thyroid tissue was obtained from patients’ preoperatively.

From Nov 2008 to present, all patients presenting to the department of Otolaryngology-Head and Neck Surgery at the Victoria General Hospital (Halifax, Canada) for thyroid surgery were asked to participate in this study. Exclusion criteria included: 1) completion hemi-thyroidectomy, 2) blood-borne infectious disease, and, 3) diagnosis of a non-PTC. Patients and tissue samples were sequentially assigned anonymous identifying numbers.

At the time of surgery, the pathological specimen of resected thyroid tissue was sent fresh from the operating theater to the pathology department where the dominant nodule margins were inked. A portion of the dominant nodule was then either snap frozen in liquid nitrogen or placed in RNAlater (Ambion) in a 2 ml micro centrifuge tube. Samples were stored at −80°C.

Final pathology reports were reviewed and thyroid specimens were grouped as either benign nodular changes or PTC. Twenty-three benign tissue samples and twenty-four tumor samples were then retrieved from storage for RNA extraction.

RNA extraction and reverse transcription

Working on ice in a class II biological safety cabinet (SteriGuard III Advance, Baker Company, Sanford, ME) a portion of each frozen tissue sample was removed (approximately 3 mm × 3 mm) with a sterile no. 10 surgical blade in a sterile tissue culture dish. This represented approximately 60 mg of tissue. The tissues were homogenized (PowerMax AHS 200®) in a 3.5 ml Röhre tube (Sarstedt) containing 600 μl of Buffer RLT (RNeasy® Plus Mini Kit, Qiagen) with 1% (6 μl) β-mercaptoethanol. The lysate was centrifuged for 3 minutes at 3273 × g. RNA was isolated using the RNeasy® Plus Mini Kit (Qiagen) according to the manufacturer’s instructions. The final RNA elution was carried out with 50 μl of RNase-free water passed twice through the RNeasy® spin column.

Sample RNA was quantified using an Epoch® plate reader using a Take3® plate and Gen5® software (version 1.10.8). Reverse transcription was carried out using the QuantiTect® Reverse Transcription Kit (Qiagen) according to the manufacturer’s instructions. Briefly, approximately 2 μg of template RNA per sample was used in a reaction volume of 40 μl. The cDNA synthesis was conducted at 42°C for 30 minutes and stopped by incubating the reaction mixture at 95°C for 3 minutes. Samples were then stored at −20°C.

Real-time PCR

A total of 1 μl template cDNA per reaction was amplified by real-time PCR in a 7900HT Fast Real-Time PCR System (Applied Biosystems; SDS 2.2.2) using RT2 SYBR® Green ROX™ qPCR Mastermix (Qiagen) with the following primers: beta-actin forward 5′-AGC GGG AAA TCG TGC GTG -3′ and reverse 5′-CAG GGT ACA TGG TGG TGC C-3′; TGF-β1 as published [[16]], and TGF-β2 forward 5′-AAGTCATACCACCTTTCCGATTG-3′ and reverse 5′-GACGGCACAGGGATTTCTTCT-3′. An initial denaturation step of 95°C for 10 minutes was carried out to activate the HotStart® Taq DNA polymerase (Qiagen), this was followed by 40 cycles of denaturation at 95°C × 15 seconds and a combined annealing and elongation step of 60°C for 60 seconds. Each sample was run in triplicate with each primer pair. The AutoCT algorithm of the program determined the baseline and threshold of Ct value for each primer pair. Samples with a Ct value >35 were rejected.

Statistical analysis

The sample mRNA expression level of TGF-β1 and TGF-β2 was assessed by averaging the triplicate CT values. Gene expression profiles were expressed using the comparative CT (2-Δ CT) method. The ΔCT was calculated using β-actin as an internal control according to Equation 1 [[17]]. Non-parametric analysis utilizing the Mann–Whitney U-test was carried out using SPSS software version 20 (SPSS Inc., Chicago, IL) to compare the TGF-β1 and TGF-β2 ΔCT values between benign and malignant nodules. Significance was set at a P-value of 0.05.
Δ C T = 2 CT gene of interest CT control gene
(1)

Results

Patient selection and sample collection

At the time of the study a total of 273 patients were asked to participate. Of these, 87 patients either refused participation or were excluded. From the remaining patients, a total of 186 thyroid samples were collected and stored. The groups’ demographics are summarized in Table 1. Average age of patients diagnosed with papillary cancer was 67.3 years old. The male: female ratio in this cancer group was 1:1.5. Tissue from 106 of these samples was available for this study. The remaining 80 samples had been used in prior experiments. Of the 186 surgeries performed, 103 (55%) were diagnosed as benign after pathological examination. Table 2 summarizes the demographics of patients whose tissues were analyzed in this study.
Table 1

Thyroid study patient demographics

Group

M:F

Age (range)

n

B

1:2.81

43.5(26–81)

103

PTC

1:1.51

67.3 (18–80)

83

Total

 

54.15

186

Thyroid samples were grouped according to pathological diagnoses: Benign (B) and papillary thyroid cancer (PTC). Average age (and range), male: female ratio (M:F), and group size (n) are shown.

Table 2

Patient demographics of thyroid nodules analyzed

Group

M:F

Age (range)

n

B

1:2.28

58.83(32–81)

23

PTC

1:1.67

53.83 (35–77)

24

Total

 

56.27

47

PTC = Papillary thyroid cancer; B = Benign; M:F = male: female ratio; n = group size.

Real time PCR

Amplified sample cDNA was quantified via the aforementioned ΔCT method. The range of gene specific ΔCT values, in benign vs. PTC nodules, is demonstrated in Table 3.
Table 3

Range of group specific 2 -ΔC T values for TGF- β1 and TGF- β2 in thyroid nodules

Group

TGF-β1 2-Δ CTrange

TGF-β2 2-Δ CTrange

PTC

7.74 x 10−4 - 1.80 x 10−1

1.39 x10−5 - 3.96 x 10−4

B

4.65 x 10−3 - 4.15 x 10−2

6.55 x 10−6 - 3.80 x 10−4

PTC = Papillary thyroid cancer; B = Benign; TGF = Transforming growth factor.

Non-parametric statistics

Mann–Whitney U-tests revealed significantly increased expression of TGFβ-1 (p < 0.0001), but not TGFβ-2 (p = 0.4735), in PTC nodules compared to benign nodules. Results are shown in Figure 1.
Figure 1

Mann–Whitney U-test analysis of 2 -Δ C T values. A) Significantly increased expression of TGFβ-1 mRNA in the PTC (cancer) group is observed (p < 0.0001). B) No significant difference in TGFβ-2 expression is observed (p = 0.4735).

Discussion

Thyroid nodules are common, affecting 4-7% of the US population, and thyroid cancer most often presents as a nodule. However, only 5% of nodules are found to be malignant. Thyroid cancer represents 2.5% of all malignancies [[2]], but the rate of thyroid cancer in Canada is steadily increasing at approximately 7% per year for males and 9% per year for females [[1]]. PTC accounts for approximately 80% of thyroid malignancies [[2]].

Fine needle aspirate (FNA) biopsies for cytological examination represents the first line investigation for thyroid nodules. For PTC, the accuracy of FNA cytology is 99%. However, approximately 20% of FNAs are non-diagnostic [[2],[5]]. Attaining an accurate preoperative diagnosis of a thyroid nodule can prove difficult due to the lack of specific diagnostic tests for thyroid cancer. Consequently, 40-60% of thyroid surgery is performed for diagnostic purposes after non-diagnostic FNA cytology [[4]–[6]]. A specific molecular marker for thyroid cancer screening is desirable to avoid the resource burden of potentially avoidable surgery.

In this pilot study, a thyroid nodule database and tissue bank was used to identify and group patients based on their diagnoses; these included benign nodules and PTC. We demonstrated that in the Nova Scotia population sampled, the average age of patients presenting for thyroid surgery, and patients diagnosed with thyroid cancer, is 54.5 and 67.3 years respectively. This represents an older cancer cohort than the traditionally taught 45–49 year old female. Additionally the male: female ratio for PTC is usually quoted as 1:3 [[2]]. We noted a slight increase in the number of men with PTC in our database, with a male: female ratio of 1:1.5. Whether this is due to sampling error or represents a true trend is yet to be discerned.

In total, 186 surgeries were performed, 103 (55%) for benign disease. Again, this highlights the burden of diagnostic thyroid surgery on operating room and in-patient resources. A recent cost analysis simulation examined the expected cost savings with the utilization of a diagnostic molecular marker for thyroid cancer in cases of indeterminate FNA cytology. Assuming a sensitivity and specificity of 95%, this study found that utilization of such a marker would result in a savings of $1087 in direct costs per patient as well as a significant gain in quality adjusted life years [[4]]. Costs to a publicly funded health care system were not addressed. However, in a recent publication from our department, the cost of an inpatient hospital bed was calculated to equal $1245 per day, with the OR fees amounting to $565 per hour before factoring nursing costs [[18]]. Clearly, substantial potential cost savings exist in the setting of improved preoperative diagnostic abilities.

TGF-β is a cytokine found to play a role in PTC. It represents a potential diagnostic molecular marker for the disease. Immunohistochemical studies examining the role of TGF-β in human thyroids and thyroid cancer have demonstrated increased cytoplasmic presence of TGF-β at the periphery of poorly circumscribed PTC. These tumors were associated with increased invasiveness and metastasis with an increased propensity towards epithelial to mesenchymal transition [[8],[10],[13]]. The association of TGF-β with epithelial to mesenchymal transition in PTC has been replicated in animal and in vitro studies [[8],[13]]. Additionally, oligonucleotide microarray studies of papillary thyroid tumor samples have demonstrated increased TGF-β expression [[14]]. TGF-β effects are context specific, acting as a potent anti-tumor agent as well as a pro-oncogenic agent depending on the stage and tumor type. In normal thyroid tissue, the effects of TGF-β are anti-proliferation, pro-apoptotic, and repressive to both thyroglobulin and sodium-iodine symporter (NIS) expression [[12],[19]]. In vitro studies have demonstrated loss of pro-apoptotic response to TGF-β in thyroid cancer cells. This leads to tumor promotion by TGF-β, postulated to be via the combined effects of immune suppression, angiogenesis and epithelial to mesenchymal transition [[8],[11]–[13],[19]].

In this pilot study, we examined the TGF-β1 and TGF-β2 expression level in 23 cases of human PTC. These were compared to nodules with benign changes on pathology. Utilizing real-time quantitative PCR and reverse transcription techniques, our data strongly demonstrated that in the presence of PTC, TGF-β1 mRNA levels are significantly elevated compared to glands with benign nodular changes. There was no difference in the expression of TGF-β2 seen between the two groups. This up-regulation of TGF-β1 gene expression is consistent with previous findings utilizing differing molecular and staining techniques [[7],[10],[14],[15]]. TGF-β1 but not TGF-β2 appears to be a promising molecular marker potentially exploitable for the diagnosis of PTC in thyroid nodules.

Currently, commercial RNA-based gene expression classifiers are available for molecular marker testing of thyroid nodules with indeterminate cytology [[20],[21]]. The American Thyroid Association recommends use of molecular marker testing for nodules with indeterminate cytology with a specific focus on expression of BRAF, RAS, RET/PTC, PAX8-PPARγ, and galectin-3 [[22]]. One commercially available array Afirma™, lists a total 167 genes in its classifier, however, TGF- β1 is not included [[20]]. The addition of testing with the current Afirma™ gene classifier has demonstrated detection of benign nodules in 52% of indeterminate nodules, thus preventing further diagnostic surgery in approximately half of the patients tested [[23]]. The results of our study suggest that analysis of TGF- β1 expression in addition to these currently screened genes may serve to further refine gene classifiers in future microarrays in order to improve the detection of benign nodules. Further investigation is needed in this regard.

The results of our current study were significant in demonstrating increased expression of TGF-β1 in PTC. However, our conclusions are limited by our sample size and by potential sampling bias. As noted, 80 collected samples were unavailable for this study. This may have potentially skewed our data. Nonetheless, we are reassured by the fact that our results appear to be congruent with the findings of previous authors’ in vitro work on PTC cell lines, animal models, and immunohistological studies [[7],[8],[10],[14],[15]]. We did not observe a difference in TGF-β2 expression between benign and malignant nodules.

To our knowledge, this study is the first to examine a fresh frozen human thyroid tissue bank and to demonstrate the significantly elevated expression of TGF-β1, but not TGF-β2, in PTC when directly compared to benign thyroid nodules. Future work with our expanding thyroid tissue bank will facilitate elucidating the role of TGF-β1 in both PTC genesis and diagnosis.

Conclusion

Our study has demonstrated that, in the Nova Scotia population presenting to our department, approximately 55% of the thyroid surgery performed is for benign thyroid changes. The average age of presentation with a malignant nodule is 67.3 years, while the average age of all comers presenting with a thyroid mass is 54.5 years. The proportion of men diagnosed with thyroid cancer compared to women is 1:1.5 respectively.

In those cases of PTC examined, TGF-β1 expression was significantly increased compared to thyroids with benign disease. Interestingly, TGF-β2 expression did not differ between the groups. TGF-β has been shown in multiple previous studies to play a role in PTC, however, to date no studies examining the potential use TGF-β1 as a cytological diagnostic marker for PTC have been completed. Future experiments examining this application are pending. The results of which will likely translate into significant cost- and resource-savings for our health care system.

Abbreviations

B: 

Benign

CT

Threshold cycle

FNA: 

Fine needle aspirate

NIS: 

Sodium iodide symporter

PTC: 

Papillary thyroid cancer

TGF-β: 

Transforming growth factor beta

Declarations

Acknowledgements

We would like to acknowledge the research assistance Karen Inglis RN, in coordinating tissue collection, transport and storage, as well as database maintenance for this project. We would also like to acknowledge the assistance of Dr. Evelyn Teh and the Canadian National Research Council for their assistance in storage and cataloguing of tissues.

Authors’ Affiliations

(1)
Department of Otolaryngology – Head and Neck Surgery;, QEII Health Sciences Centre
(2)
Department of Microbiology & Immunology, Department of Pathology, Department of Pediatrics, Canadian Center for Vaccinology, IWK Health Centre, Dr. Richard B. Goldbloom Research and Clinical Care Pavilion
(3)
Department of Pathology;

References

  1. Canadian Cancer Society’s Steering Committee on Cancer Statistics: Canadian Cancer Statistics 2012. Toronto, ON: Canadian Cancer Society; 2012.Google Scholar
  2. Lai S, Mandel S, Weber R: Management of thyroid neoplasms. Cummings Otolaryngology Head & Neck Surgery. Volume 2. 5th edition. Edited by: Flint PW, Haughey BH, Lund VJ, Niparko JK, Richardson MA, Robbins KT, Thomas JR. 2010, Mosby/Elsevier, Philadelphia, PA, 1750-1772. 10.1016/B978-0-323-05283-2.00125-7.View ArticleGoogle Scholar
  3. Coorough N, Hudak K, Jaume JC, Buehler D, Selvaggi S, Rivas J, Sippel R, Chen H: Nondiagnostic fine-needle aspirations of the thyroid: Is the risk of malignancy higher?. J Surg Res. 2013, 184 (2): 746-750. 10.1016/j.jss.2013.02.018.PubMedView ArticleGoogle Scholar
  4. Najafzadeh M, Marra CA, Lynd LD, Wiseman SM: Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer. Value Health. 2012, 15 (8): 1005-1013. 10.1016/j.jval.2012.06.017.PubMedView ArticleGoogle Scholar
  5. Cibas ES, Ali SZ: The bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009, 132 (5): 658-665. 10.1309/AJCPPHLWMI3JV4LA.PubMedView ArticleGoogle Scholar
  6. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD, Kim BW, Nosé V, Marqusee E, Larsen PR, Alexander EK: Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007, 111 (6): 508-516. 10.1002/cncr.23116.PubMedView ArticleGoogle Scholar
  7. Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Friguglietti CU, Ferro MC, Kulcsar MA, Kimura ET: Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues. Arq Bras Endocrinol Metabol. 2010, 54 (4): 406-412. 10.1590/S0004-27302010000400010.PubMedView ArticleGoogle Scholar
  8. Heldin CH, Landstrom M, Moustakas A: Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol. 2009, 21 (2): 166-167. 10.1016/j.ceb.2009.01.021.PubMedView ArticleGoogle Scholar
  9. D’Inzeo S, Nicolussi A, Donini CF, Zani M, Mancini P, Nardi F, Coppa A: A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression. Endocr Relat Cancer. 2012, 19 (1): 39-55. 10.1530/ERC-11-0233.PubMedView ArticleGoogle Scholar
  10. Eloy C, Santos J, Cameselle Teijeiro J, Soares P, Sobrinho-Simões M: TGF-beta/smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch. 2012, 460 (6): 587-600. 10.1007/s00428-012-1234-y.PubMedView ArticleGoogle Scholar
  11. Geraldo MV, Yamashita AS, Kimura ET: MicroRNA miR-146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer. Oncogene. 2012, 31 (15): 1910-1922. 10.1038/onc.2011.381.PubMedView ArticleGoogle Scholar
  12. Mincione G, Di Marcantonio MC, Tarantelli C, D’Inzeo S, Nicolussi A, Nardi F, Donini CF, Coppa A: EGF and TGF-beta1 effects on thyroid function.J Thyroid Res 2011, 2011:431718..Google Scholar
  13. Moustakas A, Heldin CH: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007, 98 (10): 1512-1520. 10.1111/j.1349-7006.2007.00550.x.PubMedView ArticleGoogle Scholar
  14. Imamura Y, Jin L, Grande JP, Li CY, Zheng TR, Erickson LA, Lloyd RV: Analysis of TGF-B and TGF-B-RII in thyroid neoplasms from the united states, japan, and china. Endocr Pathol. 1998, 9 (3): 209-216. 10.1007/BF02739960.PubMedView ArticleGoogle Scholar
  15. Kimura ET, Kopp P, Zbaeren J, Asmis LM, Ruchti C, Maciel RM, Studer H: Expression of transforming growth factor beta1, beta2, and beta3 in multinodular goiters and differentiated thyroid carcinomas: A comparative study. Thyroid. 1999, 9 (2): 119-125. 10.1089/thy.1999.9.119.PubMedView ArticleGoogle Scholar
  16. Chen D, Hu Q, Mao C, Jiao Z, Wang S, Yu L, Xu Y, Dai D, Yin L, Xu H: Increased IL-17-producing CD4(+) T cells in patients with esophageal cancer. Cell Immunol. 2012, 272 (2): 166-174. 10.1016/j.cellimm.2011.10.015.PubMedView ArticleGoogle Scholar
  17. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3 (6): 1101-1108. 10.1038/nprot.2008.73.PubMedView ArticleGoogle Scholar
  18. Phillips TJ, Sader C, Brown T, Bullock M, Wilke D, Trites JR, Hart R, Murphy M, Taylor SM: Transoral laser microsurgery versus radiation therapy for early glottic cancer in canada: Cost analysis. J Otolaryngol Head Neck Surg. 2009, 38 (6): 619-623.PubMedGoogle Scholar
  19. Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P: The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009, 69 (21): 8317-8325. 10.1158/0008-5472.CAN-09-1248.PubMedView ArticleGoogle Scholar
  20. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR: Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012, 367 (8): 705-715. 10.1056/NEJMoa1203208.PubMedView ArticleGoogle Scholar
  21. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, Hershman JM, Babu V, Blevins TC, Moore P, Andruss B, Labourier E: Centralized molecular testing for oncogenic gene mutations complements the local cytopathological diagnosis of thyroid nodules.Thyroid 2014. Jun 18 [Epub ahead of print]..Google Scholar
  22. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009, 19 (11): 1167-1214. 10.1089/thy.2009.0110.PubMedView ArticleGoogle Scholar
  23. Kloos RT, Reynolds JD, Walsh PS, Wilde JI, Tom EY, Pagan M, Barbacioru C, Chudova DI, Wong M, Friedman L, LiVolsi VA, Rosai J, Lanman RB, Kennedy GC: Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the afirma gene expression classifier in cytologically indeterminate thyroid nodules?. J Clin Endocrinol Metab. 2013, 98 (4): E761-E768. 10.1210/jc.2012-3762.PubMedView ArticleGoogle Scholar

Copyright

© Brace et al. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.